GlassScriptPhysician profile
Shiao Woo
NPI 1629175393
$6,816.02
in general payments reported to CMS, 2019-2025
30 companies · $87.01 in 2025
The $87.01 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,150 · 2020: $76.91 · 2021: $93.31 · 2022: $389 · 2023: $645 · 2024: $374 · 2025: $87.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $5,034.00 | 2019-2024 | Optune |
| Gt Medical Technologies, INC | $502.75 | 2022-2025 | Gammatile, Gammatile |
| Merck Sharp & Dohme LLC | $282.33 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $153.70 | 2019 | |
| Elekta, INC. | $125.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $71.52 | 2023-2024 | Gliadel, Vivimusta |
| Stemline Therapeutics INC. | $62.03 | 2023 | Orserdu |
| Incyte Corporation | $40.36 | 2021-2023 | Jakafi |
| Reflexion Medical, INC. | $34.40 | 2023 | Reflexion Medical Radiotherapy System |
| Celgene Corporation | $32.39 | 2019 | |
| Foundation Medicine, INC. | $32.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.06 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $31.56 | 2019-2023 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $30.54 | 2019-2024 | Alunbrig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.41 | 2021 | |
| Boston Scientific Corporation | $25.50 | 2022 | |
| Mirati Therapeutics, INC. | $23.49 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $20.84 | 2024 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $18.89 | 2023 | |
| Spectrum Pharmaceuticals INC. | $18.88 | 2023 | Rolvedon |
| Verastem, INC. | $17.86 | 2020 | |
| G1 Therapeutics, INC. | $17.45 | 2023 | Cosela |
| Eisai INC. | $14.31 | 2020 | |
| Beigene USA, INC. | $13.75 | 2023 | Brukinsa |
| Jazz Pharmaceuticals INC. | $12.63 | 2019 | |
| Ge Healthcare | $12.53 | 2019 | |
| Janssen Biotech, INC. | $11.38 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiao Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.